2-(Methylsulfanyl)-5-(propan-2-yl)thiophene | 111859-79-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(Methylsulfanyl)-5-(propan-2-yl)thiophene
• 英文别名: 2-methylsulfanyl-5-propan-2-ylthiophene
• CAS: 111859-79-1
• 化学式: C₈H₁₂S₂
• 分子量: 172.3
• InChiKey: KKNWHTWUVPHONC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Kinase Inhibitors
  申请人：Wurster A. Julie

  公开号：US20070032478A1

  公开（公告）日：2007-02-08

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调控和/或抑制异常细胞增殖。
• Imidazo[1,2-A] Pyridine Anxiolytics
  申请人：Fang Q. Kevin

  公开号：US20080096867A1

  公开（公告）日：2008-04-24

  Imidazo[1,2-a]pyridines of the formulae I and II: are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is:

  公开了式I和式II的咪唑[1,2-a]吡啶化合物。这些化合物可用于治疗焦虑和失眠。还公开了制药组合物和方法。该发明的代表性化合物为：
• Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
  申请人：Cheng T. Peter

  公开号：US20070015797A1

  公开（公告）日：2007-01-18

  Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R 1 , R 2 , R 2a , R 2b , R 2c , R 3 , Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

  提供了一些化合物，它们的结构如下：其中Q为C或N，A为O或S，Z为O或键，X为CH或N，R1、R2、R2a、R2b、R2c、R3、Y、x、m和n如此定义，这些化合物可用作抗糖尿病、降脂和抗肥胖药物。
• IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS
  申请人：Fang Kevin

  公开号：US20070043074A1

  公开（公告）日：2007-02-22

  Imidazo[1,2- a ]pyridines of the formulae I and II: are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is:

  公开了式I和式II的咪唑[1,2-a]吡啶类化合物。该化合物可用于治疗焦虑和失眠。还公开了制药组合物和方法。该发明的代表化合物为：
• Kinase inhibitors
  申请人：Spada Lon T.

  公开号：US20090208557A1

  公开（公告）日：2009-08-20

  The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

  本发明涉及药物输送系统，包括眼内植入物，其中包括有机分子，能够调节酪氨酸激酶信号传导以调节、调控和/或抑制异常细胞增殖，并与聚合物组合使用，该聚合物用于控制、修改、调节和/或减缓治疗成分释放到放置该复合物的眼部环境中。